GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » E10

Oncternal Therapeutics (FRA:GTU) E10 : €-145.05 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncternal Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-2.604. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-145.05 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 18.40% per year. During the past 5 years, the average E10 Growth Rate was 12.30% per year. During the past 10 years, the average E10 Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oncternal Therapeutics was 31.70% per year. The lowest was 3.60% per year. And the median was 16.60% per year.

As of today (2024-05-25), Oncternal Therapeutics's current stock price is €5.32. Oncternal Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-145.05. Oncternal Therapeutics's Shiller PE Ratio of today is .


Oncternal Therapeutics E10 Historical Data

The historical data trend for Oncternal Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics E10 Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -405.58 -385.22 -369.10 -310.22 -209.47

Oncternal Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -293.50 -236.66 -225.38 -209.47 -145.05

Competitive Comparison of Oncternal Therapeutics's E10

For the Biotechnology subindustry, Oncternal Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Shiller PE Ratio falls into.



Oncternal Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncternal Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.604/131.7762*131.7762
=-2.604

Current CPI (Mar. 2024) = 131.7762.

Oncternal Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -154.560 100.560 -202.540
201409 -65.184 100.428 -85.531
201412 -147.602 99.070 -196.331
201503 -25.872 99.621 -34.223
201506 -424.116 100.684 -555.088
201509 -49.896 100.392 -65.495
201512 -51.408 99.792 -67.884
201603 18.858 100.470 24.734
201606 -53.578 101.688 -69.431
201609 -61.123 101.861 -79.074
201612 -58.397 101.863 -75.546
201703 -51.051 102.862 -65.401
201706 -49.840 103.349 -63.549
201709 -62.254 104.136 -78.778
201712 -50.869 104.011 -64.448
201803 -70.395 105.290 -88.104
201806 -51.531 106.317 -63.871
201809 -46.792 106.507 -57.894
201812 -27.073 105.998 -33.657
201903 -29.736 107.251 -36.536
201906 -59.826 108.070 -72.950
201909 -5.811 108.329 -7.069
201912 3.060 108.420 3.719
202003 -5.611 108.902 -6.790
202006 -6.038 108.767 -7.315
202009 -3.736 109.815 -4.483
202012 -1.480 109.897 -1.775
202103 -2.016 111.754 -2.377
202106 -2.656 114.631 -3.053
202109 -3.230 115.734 -3.678
202112 -2.832 117.630 -3.173
202203 -3.632 121.301 -3.946
202206 -4.352 125.017 -4.587
202209 -4.242 125.227 -4.464
202212 -3.776 125.222 -3.974
202303 -3.671 127.348 -3.799
202306 -2.769 128.729 -2.835
202309 -3.186 129.860 -3.233
202312 -2.779 129.419 -2.830
202403 -2.604 131.776 -2.604

Add all the adjusted EPS together and divide 10 will get our e10.


Oncternal Therapeutics  (FRA:GTU) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncternal Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (FRA:GTU) Business Description

Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines